NASDAQ:UNCY Unicycive Therapeutics (UNCY) Stock Price, News & Analysis → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free UNCY Stock Alerts $0.98 +0.01 (+1.44%) (As of 12:20 PM ET) Add Compare Share Share Today's Range$0.95▼$1.0050-Day Range$0.97▼$1.7952-Week Range$0.47▼$1.82Volume60,433 shsAverage Volume353,732 shsMarket Capitalization$34.20 millionP/E RatioN/ADividend YieldN/APrice Target$5.30 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Unicycive Therapeutics alerts: Email Address Unicycive Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside440.8% Upside$5.30 Price TargetShort InterestHealthy1.53% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.58) to ($0.30) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.24 out of 5 starsMedical Sector553rd out of 908 stocksPharmaceutical Preparations Industry251st out of 424 stocks 3.5 Analyst's Opinion Consensus RatingUnicycive Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageUnicycive Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.53% of the float of Unicycive Therapeutics has been sold short.Short Interest Ratio / Days to CoverUnicycive Therapeutics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Unicycive Therapeutics has recently increased by 49.10%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldUnicycive Therapeutics does not currently pay a dividend.Dividend GrowthUnicycive Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for UNCY. Previous Next 1.1 News and Social Media Coverage News SentimentUnicycive Therapeutics has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Unicycive Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for UNCY on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows8 people have added Unicycive Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 167% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Unicycive Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders42.00% of the stock of Unicycive Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions40.42% of the stock of Unicycive Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Unicycive Therapeutics are expected to grow in the coming year, from ($0.58) to ($0.30) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Unicycive Therapeutics is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Unicycive Therapeutics is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About Unicycive Therapeutics Stock (NASDAQ:UNCY)Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.Read More UNCY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart UNCY Stock News HeadlinesApril 16, 2024 | americanbankingnews.comUnicycive Therapeutics (NASDAQ:UNCY) Given "Speculative Buy" Rating at BenchmarkApril 12, 2024 | markets.businessinsider.comBuy Rating Affirmed for Unicycive Therapeutics on Strong Trial Progress and Financial PositioningApril 26, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.April 10, 2024 | globenewswire.comUnicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity ConferenceApril 4, 2024 | markets.businessinsider.comUnicycive Therapeutics: A Strong Buy on OLC’s Potential to Revolutionize Hyperphosphatemia Treatment in CKDApril 2, 2024 | markets.businessinsider.comBuy Rating Affirmed for Unicycive Therapeutics Amidst Positive Milestones and Solid Financial FootingMarch 28, 2024 | investorplace.comUNCY Stock Earnings: Unicycive Therapeutics Misses EPS for Q4 2023March 28, 2024 | finance.yahoo.comUnicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business UpdateApril 26, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.March 28, 2024 | globenewswire.comUnicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business UpdateMarch 25, 2024 | globenewswire.comUnicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association CongressMarch 16, 2024 | investing.comUnicycive reports progress in kidney injury treatment trialMarch 14, 2024 | markets.businessinsider.comBuy Rating on Unicycive Therapeutics Amidst Promising UNI-494 Drug Candidate ProspectsMarch 14, 2024 | globenewswire.comUnicycive Announces $50 Million Private PlacementMarch 13, 2024 | globenewswire.comUnicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT ConferenceMarch 9, 2024 | finanznachrichten.deUnicycive Therapeutics, Inc.: Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)March 7, 2024 | globenewswire.comUnicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)March 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for Unicycive Therapeutics Amidst Promising UNI-494 Developments and FDA Orphan Drug DesignationMarch 4, 2024 | globenewswire.comUnicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant PatientsFebruary 25, 2024 | benzinga.comUnicycive Therapeutics Stock (NASDAQ:UNCY), Short Interest ReportFebruary 25, 2024 | benzinga.comUnicycive Therapeutics Stock (NASDAQ:UNCY), Analyst Ratings, Price Targets, PredictionsFebruary 24, 2024 | msn.comUnicycive Therapeutics (UNCY) Price Target Increased by 14.13% to 4.46February 14, 2024 | finance.yahoo.comUnicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical MeetingFebruary 14, 2024 | globenewswire.comUnicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical MeetingFebruary 6, 2024 | finance.yahoo.comWe're Keeping An Eye On Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn RateJanuary 29, 2024 | finance.yahoo.comUnicycive Therapeutics Announces Both an Oral and Poster Presentation to be Delivered on UNI-494 at the Upcoming AKI and CRRT ConferenceJanuary 24, 2024 | finance.yahoo.comUnicycive (UNCY) Up on Positive Hyperphosphatemia Study UpdateSee More Headlines Receive UNCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Unicycive Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today4/26/2024Next Earnings (Estimated)5/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:UNCY CUSIPN/A CIK1766140 Webwww.unicycive.com Phone650-351-4495FaxN/AEmployees12Year FoundedN/APrice Target and Rating Average Stock Price Target$5.30 High Stock Price Target$9.00 Low Stock Price Target$3.00 Potential Upside/Downside+446.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,540,000.00 Net MarginsN/A Pretax Margin-4,525.04% Return on EquityN/A Return on Assets-96.37% Debt Debt-to-Equity RatioN/A Current Ratio0.76 Quick Ratio0.76 Sales & Book Value Annual Sales$680,000.00 Price / Sales49.58 Cash FlowN/A Price / Cash FlowN/A Book Value($0.11) per share Price / Book-8.82Miscellaneous Outstanding Shares34,760,000Free Float20,158,000Market Cap$33.72 million OptionableNot Optionable Beta2.66 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Shalabh K. Gupta M.D. (Age 51)MPA, Founder, Chairman, CEO & President Comp: $1.46MDr. Pramod Gupta Ph.D. (Age 64)Executive Vice President of Pharmaceutical & Business Operations Comp: $779.18kMr. Douglas Jermasek M.B.A. (Age 62)Executive Vice President of Corporate Strategy Comp: $430.81kMr. John W. Townsend CPA (Age 62)Chief Financial Officer Comp: $197.86kKey CompetitorsBriaCell TherapeuticsNASDAQ:BCTXXilio TherapeuticsNASDAQ:XLOOcuphire PharmaNASDAQ:OCUPCara TherapeuticsNASDAQ:CARAJanOneNASDAQ:JANView All CompetitorsInstitutional OwnershipRosalind Advisors Inc.Bought 1,879,646 shares on 4/25/2024Ownership: 5.407%BVF Inc. ILSold 1,295,424 shares on 2/15/2024Ownership: 6.095%View All Institutional Transactions UNCY Stock Analysis - Frequently Asked Questions Should I buy or sell Unicycive Therapeutics stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Unicycive Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" UNCY shares. View UNCY analyst ratings or view top-rated stocks. What is Unicycive Therapeutics' stock price target for 2024? 4 brokerages have issued twelve-month target prices for Unicycive Therapeutics' shares. Their UNCY share price targets range from $3.00 to $9.00. On average, they predict the company's share price to reach $5.30 in the next twelve months. This suggests a possible upside of 440.8% from the stock's current price. View analysts price targets for UNCY or view top-rated stocks among Wall Street analysts. How have UNCY shares performed in 2024? Unicycive Therapeutics' stock was trading at $0.8677 at the beginning of the year. Since then, UNCY shares have increased by 12.9% and is now trading at $0.98. View the best growth stocks for 2024 here. Are investors shorting Unicycive Therapeutics? Unicycive Therapeutics saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 382,900 shares, an increase of 49.1% from the March 31st total of 256,800 shares. Based on an average trading volume of 383,000 shares, the days-to-cover ratio is presently 1.0 days. Approximately 1.5% of the shares of the company are sold short. View Unicycive Therapeutics' Short Interest. When is Unicycive Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024. View our UNCY earnings forecast. How were Unicycive Therapeutics' earnings last quarter? Unicycive Therapeutics, Inc. (NASDAQ:UNCY) issued its earnings results on Thursday, March, 28th. The company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.18) by $0.02. When did Unicycive Therapeutics IPO? Unicycive Therapeutics (UNCY) raised $25 million in an IPO on Tuesday, July 13th 2021. The company issued 4,600,000 shares at a price of $5.00-$6.00 per share. Roth Capital Partners acted as the underwriter for the IPO and EF Hutton (formerly Kingswood Capital Markets) was co-manager. Who are Unicycive Therapeutics' major shareholders? Unicycive Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Rosalind Advisors Inc. (5.41%). View institutional ownership trends. How do I buy shares of Unicycive Therapeutics? Shares of UNCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:UNCY) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupTrump is sounding the alarmPreserve Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Unicycive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
